摘要
目的观察芎芍胶囊治疗冠心病心绞痛心血瘀阻证的临床疗效及安全性。方法将5家研究中心240例冠心病心绞痛心血瘀阻证患者随机分为试验组(120例,完成112例,脱落8例)和对照组(120例,完成115例,脱落2例,剔除3例),分别口服芎芍胶囊、血府逐瘀胶囊安慰剂与血府逐瘀胶囊、芎芍胶囊安慰剂治疗,疗程均为4周。观察治疗后心绞痛疗效、硝酸甘油服用量及其停减率,比较治疗前后中医证候、心电图、血脂、血液流变学指标等变化。结果治疗后试验组在心绞痛疗效(87.50%vs72.17%)及心电图(73.21%vs56.52%)改善方面优于对照组,差异均有统计学意义(P<0.05,P<0.01);两组间在硝酸甘油停减率、中医证候及单项症状疗效比较差异均无统计学意义(P>0.05)。治疗前后两组血液流变学与血脂各项指标以及两组间比较差异均无统计学意义(P>0.05)。试验组与对照组不良反应发生率比较,差异无统计学意义(0.018%vs0.009%,P>0.05)。结论芎芍胶囊治疗冠心病心绞痛心血瘀阻证安全有效。
Objective To observe the clinical effects and safety of Xiongshao Capsule （XSC） in treating patients with coronary heart disease angina of Xin-blood stasis syndrome. Methods Two hundred and forty patients were randomized equally into two groups,the treatment group and control group. They were treated with XSC and Xuefu Zhuyu Capsule respectively for 4 weeks. The therapeutic effect on angina pectoris,the dosage of nitroglycerin used and its withdrawal rate were observed,and changes in Chinese medical syndrome,electrocardiogram （ECG）,blood lipids,and hemorrheologic figure were observed before and after treatment. ResultsThe favorable effects on angina pectoris,ECG,Chinese medical syndromes,and clinical symptoms were observed in the treatment groups,showing significant statistical difference in improving angina pectoris and ECG to the control group （P0.05 or P0.01）. Conclusion XSC was effective and safe in treating coronary heart disease angina of Xin-blood stasis syndrome.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2011年第2期191-194,共4页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
冠心病
心绞痛
芎芍胶囊
血府逐瘀胶囊
coronary heart disease
angina pectoris
Xiongshao Capsule
Xuefu Zhuyu Capsule
